[A17-08] Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Last updated 01.06.2017
Commission awarded on 01.03.2017 by the Federal Joint Committee (G-BA).
Skin and hair
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.